U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H15NO2S
Molecular Weight 273.3517
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ARMODAFINIL

SMILES

c1ccc(cc1)C(c2ccccc2)[S@](=O)CC(=N)O

InChI

InChIKey=YFGHCGITMMYXAQ-LJQANCHMSA-N
InChI=1S/C15H15NO2S/c16-14(17)11-19(18)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H2,16,17)/t19-/m1/s1

HIDE SMILES / InChI

Molecular Formula C15H15NO2S
Molecular Weight 273.3517
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020717A_Provigil_prntlbl.pdf

Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactivation and euphoria. Modafinil is not indicated for complaints of lack of energy or fatigue; but it appears to be very helpful for some patients. Also, it has been used in the treatment of hypersomnia, a disorder in which patients lack the capacity for meaningful sleep and may require ten or more hours per day. Recent studies have have found that modafinil may help recovering cocaine addicts fight their addiction. The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular dopamine. Modafinil activates glutamatergic circuits while inhibiting GABA. Modafinil is thought to have less potential for abuse than other stimulants due to the absence of any significant euphoric or pleasurable effects. It is possible that modafinil acts by a synergistic combination of mechanisms including direct inhibition of dopamine reuptake, indirect inhibition of noradrenalin reuptake in the VLPO and orexin activation. Modafinil has partial alpha 1B-adrenergic agonist effects by directly stimulating the receptors. Modafinil is indicated for the improvement of wakefulness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
51.79 µM [IC50]
51.79 µM [IC50]
13.0 µM [Ki]
4.0 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PROVIGIL

Approved Use

Provigil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD).

Launch Date

9.1437118E11
Primary
PROVIGIL

Approved Use

Provigil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD).

Launch Date

9.1437118E11
Primary
NUVIGIL

Approved Use

NUVIGIL is indicated to improve wakefulness in patients with excessive sleepiness associated with obstructive sleep apnea, narcolepsy and shift work disorder. In OSA, NUVIGIL is indicated as an adjunct to standard treatment(s) for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating NUVIGIL. If NUVIGIL is used adjunctively with CPAP, the encouragement of and periodic assessment of CPAP compliance is necessary. In all cases, careful attention to the diagnosis and treatment of the underlying sleep disorder(s) is of utmost importance. Prescribers should be aware that some patients may have more than one sleep disorder contributing to their excessive sleepiness. The effectiveness of NUVIGIL in long-term use (greater than 12 weeks) has not been systematically evaluated in placebo-controlled trials. The physician who elects to prescribe NUVIGIL for an extended time in patients should periodically re-evaluate long-term usefulness for the individual patient.

Launch Date

1.18186561E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7.4 μg/mL
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
10.5 μg/mL
250 mg 1 times / day multiple, oral
dose: 250 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
10 μg/mL
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
13.4 μg/mL
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.8 μg/mL
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4 μg/mL
100 mg 1 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
6.9 μg/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
7 μg/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.1 μg/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2.4 μg/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2.2 μg/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: HIGH-FAT
4.1 μg/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
105.9 μg × h/mL
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
136.1 μg × h/mL
250 mg 1 times / day multiple, oral
dose: 250 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
150.4 μg × h/mL
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
189.5 μg × h/mL
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
23.4 μg × h/mL
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
56.2 μg × h/mL
100 mg 1 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
142.9 μg × h/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
146 μg × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
15.9 μg × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
40.6 μg × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
43.8 μg × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: HIGH-FAT
75.9 μg × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
13.8 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 21 years
n = 1
Health Status: unhealthy
Condition: idiopathic hypersomnia
Age Group: 21 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Stevens-Johnson syndrome...
AEs leading to
discontinuation/dose reduction:
Stevens-Johnson syndrome (1 patient)
Sources:
400 mg single, oral
Highest studied dose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources:
healthy, 21–40 years
n = 6
Health Status: healthy
Age Group: 21–40 years
Sex: M
Population Size: 6
Sources:
400 mg 1 times / day steady, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
healthy, 21–40 years
n = 4
Health Status: healthy
Age Group: 21–40 years
Sex: M
Population Size: 4
Sources:
Disc. AE: Adverse event...
AEs leading to
discontinuation/dose reduction:
Adverse event
Sources:
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy
n = 645
Health Status: unhealthy
Population Size: 645
Sources:
Disc. AE: Headache...
AEs leading to
discontinuation/dose reduction:
Headache (1%)
Sources:
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources: Page: p.6
unhealthy
n = 645
Health Status: unhealthy
Population Size: 645
Sources: Page: p.6
Disc. AE: Rash, Angioneurotic edema...
AEs leading to
discontinuation/dose reduction:
Rash (2%)
Angioneurotic edema (1%)
Hyperhidrosis (1%)
Rash papular (1%)
Sources: Page: p.6
AEs

AEs

AESignificanceDosePopulation
Stevens-Johnson syndrome 1 patient
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 21 years
n = 1
Health Status: unhealthy
Condition: idiopathic hypersomnia
Age Group: 21 years
Sex: F
Population Size: 1
Sources:
Adverse event Disc. AE
400 mg 1 times / day steady, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
healthy, 21–40 years
n = 4
Health Status: healthy
Age Group: 21–40 years
Sex: M
Population Size: 4
Sources:
Headache 1%
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy
n = 645
Health Status: unhealthy
Population Size: 645
Sources:
Angioneurotic edema 1%
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources: Page: p.6
unhealthy
n = 645
Health Status: unhealthy
Population Size: 645
Sources: Page: p.6
Hyperhidrosis 1%
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources: Page: p.6
unhealthy
n = 645
Health Status: unhealthy
Population Size: 645
Sources: Page: p.6
Rash papular 1%
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources: Page: p.6
unhealthy
n = 645
Health Status: unhealthy
Population Size: 645
Sources: Page: p.6
Rash 2%
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources: Page: p.6
unhealthy
n = 645
Health Status: unhealthy
Population Size: 645
Sources: Page: p.6
PubMed

PubMed

TitleDatePubMed
Modafinil augmentation of mirtazapine in a failure-to-thrive geriatric inpatient.
2002
Benefits and risks of pharmacotherapy for narcolepsy.
2002
Effects of modafinil on heat thermoregulatory responses in humans at rest.
2002 Aug
Drugs under investigation for attention-deficit hyperactivity disorder.
2002 Aug
Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial.
2002 Dec
Role of brain alpha 1B-adrenoceptors in modafinil-induced behavioral activity.
2002 Dec 15
Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy.
2002 Dec 24
Narcolepsy and psychopathology: is there an association?
2002 Jul
Comparison of the effects of modafinil and sleep deprivation on sleep and cortical EEG spectra in mice.
2002 Jul
Gateways to clinical trials.
2002 Jul-Aug
Attention deficit disorder in adults.
2002 Jun
Effect of modafinil on core temperature during sustained wakefulness and exercise in a warm environment.
2002 Nov
Modafinil for social phobia and amphetamine dependence.
2002 Nov
Stress-induced subsensitivity to modafinil and its prevention by corticosteroids.
2002 Nov
Circadian rhythm of rectal temperature during sleep deprivation with modafinil.
2002 Oct
Temporal pattern of hippocampal high-frequency oscillations during sleep after stimulant-evoked waking.
2003
Narcolepsy in the older adult: epidemiology, diagnosis and management.
2003
Fatigue in multiple sclerosis: definition, pathophysiology and treatment.
2003
[Therapy of day time fatigue in patients with multiple sclerosis].
2003
Clinical pharmacokinetic profile of modafinil.
2003
Three case reports of modafinil use in treating sedation induced by antipsychotic medications.
2003 Apr
Non-stimulant treatment of attention-deficit/hyperactivity disorder.
2003 Apr
Modafinil affects mood, but not cognitive function, in healthy young volunteers.
2003 Apr
Chiral analysis of d- and l-modafinil in human serum: application to human pharmacokinetic studies.
2003 Apr
An open-label trial of modafinil augmentation in patients with partial response to antidepressant therapy.
2003 Apr
Modafinil in children with attention-deficit hyperactivity disorder.
2003 Aug
TetraTab--cognitive enhancement gone wrong.
2003 Aug
[Modafinil: pharmacology and therapeutic perspectives].
2003 Jan
By the way, doctor. What can you tell me about the new drug Provigil? I've read that it helps people stay awake without feeling jittery. For those of us who work a lot of overtime, it sounds like a dream come true.
2003 Jan
Pharmacogenomics in the treatment of narcolepsy.
2003 Jan
Cognitive enhancing effects of modafinil in healthy volunteers.
2003 Jan
Should a pharmaceutical be approved for the broad indication of excessive sleepiness?
2003 Jan 15
Con: modafinil has no role in management of sleep apnea.
2003 Jan 15
Pro: modafinil has a role in management of sleep apnea.
2003 Jan 15
Modafinil treatment of opioid-induced sedation.
2003 Jun
Reduction in excess daytime sleepiness by modafinil in patients with myotonic dystrophy.
2003 Jun
Modafinil--medical considerations for use in sustained operations.
2003 Jun
Modafinil for treatment of cognitive side effects of antiepileptic drugs in a patient with seizures and stroke.
2003 Jun
Initiating treatment with modafinil for control of excessive daytime sleepiness in patients switching from methylphenidate: an open-label safety study assessing three strategies.
2003 Jun
Cataplexy worsened by modafinil.
2003 Jun 15
Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease.
2003 Mar
Distinctive effects of modafinil and d-amphetamine on the homeostatic and circadian modulation of the human waking EEG.
2003 Mar
Modafinil maintains waking in the fruit fly drosophila melanogaster.
2003 Mar 15
Modafinil increases histamine release in the anterior hypothalamus of rats.
2003 Mar 20
Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study.
2003 May 1
The safety and efficacy of modafinil in multiple sclerosis-related fatigue.
2003 Oct
Narcolepsy drug could be approved for wider use.
2003 Oct 4
The quest for a smart pill.
2003 Sep
You'll lose sleep over this pill.
2003 Sep 29
Dosing regimen effects of modafinil for improving daytime wakefulness in patients with narcolepsy.
2003 Sep-Oct
Patents

Sample Use Guides

The recommended dosage of NUVIGIL (armodafinil) for each indication is as follows: obstructive sleep apnea or Narcolepsy: 150 mg to 250 mg once a day in the morning. Shift work disorder: 150 mg once a day, taken approximately one hour prior to start of the work shift.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Jun 25 22:02:32 UTC 2021
Edited
by admin
on Fri Jun 25 22:02:32 UTC 2021
Record UNII
V63XWA605I
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ARMODAFINIL
INN   MART.   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
ACETAMIDE, 2-((R)-(DIPHENYLMETHYL)SULFINYL)-
Systematic Name English
CEP-10953
Code English
ARMODAFINIL [WHO-DD]
Common Name English
NSC-751850
Code English
CEP-10952
Code English
CRL-40982
Code English
NUVIGIL
Brand Name English
ARMODAFINIL [USP-RS]
Common Name English
MODAFINIL, (R)-
Common Name English
(-)-2-((R)-(DIPHENYLMETHYL)SULFINYL)ACETAMIDE
Systematic Name English
NSC-758711
Code English
ARMODAFINIL [MART.]
Common Name English
R-(-)-MODAFINIL
Common Name English
ARMODAFINIL [INN]
Common Name English
ARMODAFINIL [ORANGE BOOK]
Common Name English
ARMODAFINIL [USAN]
Common Name English
ACETAMIDE, 2-((DIPHENYLMETHYL)SULFINYL)-, (-)-
Systematic Name English
ARMODAFINIL [VANDF]
Common Name English
Classification Tree Code System Code
WHO-ATC N06BA13
Created by admin on Fri Jun 25 22:02:33 UTC 2021 , Edited by admin on Fri Jun 25 22:02:33 UTC 2021
NCI_THESAURUS C47795
Created by admin on Fri Jun 25 22:02:33 UTC 2021 , Edited by admin on Fri Jun 25 22:02:33 UTC 2021
LIVERTOX 63
Created by admin on Fri Jun 25 22:02:33 UTC 2021 , Edited by admin on Fri Jun 25 22:02:33 UTC 2021
Code System Code Type Description
CAS
112111-43-0
Created by admin on Fri Jun 25 22:02:33 UTC 2021 , Edited by admin on Fri Jun 25 22:02:33 UTC 2021
PRIMARY
PUBCHEM
9690109
Created by admin on Fri Jun 25 22:02:33 UTC 2021 , Edited by admin on Fri Jun 25 22:02:33 UTC 2021
PRIMARY
DRUG CENTRAL
4501
Created by admin on Fri Jun 25 22:02:33 UTC 2021 , Edited by admin on Fri Jun 25 22:02:33 UTC 2021
PRIMARY
INN
8474
Created by admin on Fri Jun 25 22:02:33 UTC 2021 , Edited by admin on Fri Jun 25 22:02:33 UTC 2021
PRIMARY
DRUG BANK
DB06413
Created by admin on Fri Jun 25 22:02:33 UTC 2021 , Edited by admin on Fri Jun 25 22:02:33 UTC 2021
PRIMARY
LACTMED
Armodafinil
Created by admin on Fri Jun 25 22:02:33 UTC 2021 , Edited by admin on Fri Jun 25 22:02:33 UTC 2021
PRIMARY
RXCUI
641465
Created by admin on Fri Jun 25 22:02:33 UTC 2021 , Edited by admin on Fri Jun 25 22:02:33 UTC 2021
PRIMARY RxNorm
NCI_THESAURUS
C65241
Created by admin on Fri Jun 25 22:02:33 UTC 2021 , Edited by admin on Fri Jun 25 22:02:33 UTC 2021
PRIMARY
ChEMBL
CHEMBL1201192
Created by admin on Fri Jun 25 22:02:33 UTC 2021 , Edited by admin on Fri Jun 25 22:02:33 UTC 2021
PRIMARY
WIKIPEDIA
ARMODAFINIL
Created by admin on Fri Jun 25 22:02:33 UTC 2021 , Edited by admin on Fri Jun 25 22:02:33 UTC 2021
PRIMARY
USP_CATALOG
1042758
Created by admin on Fri Jun 25 22:02:33 UTC 2021 , Edited by admin on Fri Jun 25 22:02:33 UTC 2021
PRIMARY USP-RS
FDA UNII
V63XWA605I
Created by admin on Fri Jun 25 22:02:33 UTC 2021 , Edited by admin on Fri Jun 25 22:02:33 UTC 2021
PRIMARY
EVMPD
SUB32249
Created by admin on Fri Jun 25 22:02:33 UTC 2021 , Edited by admin on Fri Jun 25 22:02:33 UTC 2021
PRIMARY
Related Record Type Details
RACEMATE -> ENANTIOMER
TARGET -> INHIBITOR
TARGET -> INHIBITOR
BINDER->LIGAND
BINDING
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC